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ABSTRACT: Drug resistance due to overexpression of membrane
transporters in cancer cells and the existence of cancer stem cells
(CSCs) is a major hurdle to effective and safe cancer chemotherapy.
Nanoparticles have been explored to overcome cancer drug
resistance. However, drug slowly released from nanoparticles can
still be efficiently pumped out of drug-resistant cells. Here, a hybrid
nanoparticle of phospholipid and polymers is developed to achieve
cold-triggered burst release of encapsulated drug. With ice cooling to
below ∼12 °C for both burst drug release and reduced membrane
transporter activity, binding of the drug with its target in drug-
resistant cells is evident, while it is minimal in the cells kept at 37 °C.
Moreover, targeted drug delivery with the cold-responsive nano-
particles in combination with ice cooling not only can effectively kill
drug-resistant ovarian cancer cells and their CSCs in vitro but also
destroy both subcutaneous and orthotopic ovarian tumors in vivo with no evident systemic toxicity.
■ INTRODUCTION
Development of drug resistance in cancer cells is a major
challenge to cancer chemotherapy.1−3 Research on the
mechanisms of drug resistance is usually focused on drug
metabolism including its uptake, efflux, and detoxification.1,4 A
major advance in the understanding of drug metabolism is the
identification of the membrane transporter P-glycoprotein (P-
gp) that could pump free drug out of cancer cells.5−7 However,
it is worth noting that multiple mechanisms contribute to
cancer drug resistance.8,9 A critical advance in this aspect is the
finding of the subpopulations of cancer cells that are highly
tumorigenic and drug resistant. These cancer cells are usually
referred to as cancer stem cells (CSCs) or tumor initiating/
reinitiating cells.10−12 There is mounting evidence showing that
the CSCs are responsible for cancer metastasis and tumor
recurrence or relapse associated with conventional chemo-,
radio-, and hormone therapies.13−15 Several properties of the
CSCs contribute to their high resistance to chemotherapeutic
drugs including the overexpression of drug efflux pumps,
enhanced DNA repair ability, overexpressed antiapoptotic
proteins, and dormancy.11,16,17 Therefore, it is important to
account for the multiple mechanisms responsible for the drug
resistance of cancer when developing strategies for effective
cancer therapy.
Received: January 18, 2018
Published: April 17, 2018
Research Article
Cite This: ACS Cent. Sci. 2018, 4, 567−581
© 2018 American Chemical Society 567 DOI: 10.1021/acscentsci.8b00050
ACS Cent. Sci. 2018, 4, 567−581
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
Nanoparticle-based drug delivery systems have been explored
for reducing the side effect of chemotherapeutic drugs as well as
overcoming drug efflux pump-associated drug resistance.18−22
The latter is because nanoparticles can be actively taken up by
drug-resistant cancer cells via endocytosis instead of passive
diffusion across the plasma membrane. Consequently, the drug
encapsulated in nanoparticles can bypass the efflux pumps on
the cell plasma membrane and enter the inner cytoplasm.23
However, the function of the drug efflux pumps is not
compromised during the uptake of the nanoparticles, and they
can still pump out the drug slowly released from the
nanoparticles in cells. Therefore, it may be important to
achieve burst release (i.e., release in a short time of seconds or
minutes) of a large amount of free drug inside cancer cells, so
that a significant amount of free drug could bind with its target
(e.g., DNA, RNA, or proteins) before its depletion by the efflux
pumps, for overcoming drug resistance.
Stimuli-responsive nanoparticles hold great promise for
controlling drug release inside cells.24,25 However, drug release
from most existing stimuli-responsive nanoparticles (mainly
pH- and heat-responsive ones) may still occur over hours to
days.26,27 This slowly released drug could be easily depleted by
the efflux pumps before it binds with its target in cells.
Moreover, no study has been conducted to test the existing
Figure 1. Synthesis and characterization of cold-responsive nanoparticle. (a) Hyaluronic acid (HA or H), lipid (dipalmitoylphosphatidylcholine or
DPPC in this study, L), Pluronic F127 (PF127, P), poly(N-isopropylacrylamide-co-butyl acrylate) (PNIPAM-B or N), and chitosan (C)-modified
Pluronic F127 (PF127-chitosan) were used to prepare the doxorubicin (DOX, D) laden HCLPN-D nanoparticles using the double-emulsion
method. (b) TEM images showing the HCLPN-D nanoparticles are spherical with a multicore−shell configuration. (c) The thermally induced phase
transition behavior of PNIPAM-B from being water-insoluble to highly water-soluble, which can cause disassembly of the HCLPN-D nanoparticles
upon cooling to below room temperature. This can result in burst release of the encapsulated drug. (d) TEM images showing the HCLPN-D
nanoparticles become completely disassembled after 3 min incubation at 10 °C. (e) An extensive network of polymer fibers rather than nanoparticles
is observable after warming back to 22 °C. (f) Photographs of the aqueous samples of HCLPN-D nanoparticles at various temperatures before and
after shining a red laser beam through them in the dark. As a result of the Tyndall effect (i.e., scattering of laser beam by nanoparticles in solution), a
bright white track of light is visible in the dark in the solutions of HCLPN-D nanoparticles above 10 °C. However, it is not clearly observable at or
below 10 °C and after warming back to 22 or 37 °C, indicating the HCLPN-D nanoparticles disassemble upon cooling to 10 °C (or a lower
temperature), and the disassembling process is not reversible. (g) Size distribution of HCLPN-D nanoparticles measured by dynamic light scattering
(DLS) at different temperatures. The results show a narrow size distribution of the HCLPN-D nanoparticles at 37, 22, and 15 °C. An additional peak
of large particles is seen at 12 °C, probably due to aggregation of polymers. No stable peak of nanoparticles can be detected when the temperature is
decreased to 10 and 6 °C.
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stimuli-responsive nanoparticles for overcoming drug resistance
using CSCs. More recently, cold and freezing-temperature
treatments (e.g., cryosurgery, cryotherapy, cryoablation, and
hypothermia) have been widely studied and used for treating
various diseases including cancer.28−34 Nonetheless, nano-
particles that are responsive to cold (i.e., lower than room
temperatures) have never been reported, although there are
studies on nanoparticles responsive to temperatures higher than
room temperature but blow body temperature.35−37 Further-
more, the use of cold and nanoparticle drug delivery for
overcoming cancer drug resistance has never been explored in
the literature.
In this work, we developed a cold-responsive nanoparticle
that quickly disassembles upon ice cooling, leading to burst
release of most of the encapsulated chemotherapeutic drug
(doxorubicin hydrochloride or DOX) in seconds. Moreover,
the NCI/RES-ADR multidrug-resistant cancer cells (human
ovarian cancer cells that were called MCF-7/ADR cells in early
studies) and their CSCs together with A2780ADR drug
resistant ovarian cancer cells, were used in this study to
demonstrate the capability of overcoming cancer drug
resistance with the cold-responsive nanoparticle in vitro and
in vivo.
■ RESULTS
Preparation and Characterization of Nanoparticles. As
shown in Figure 1a, the cold-responsive nanoparticles were
prepared with the double-emulsion method using dipalmitoyl-
phosphatidylcholine (DPPC) and four different polymers
including Pluronic F127 (PF127), poly(N-isopropylacryla-
mide-co-butyl acrylate) (PNIPAM-B, NIPAM:B = 8:1, Mn =
30,000), chitosan-modified PF127 (PF127-chitosan), and
hyaluronic acid (HA). All four polymers have been widely
used for various biomedical applications and are considered as
biocompatible biomaterials, and PF127, chitosan, and HA have
been approved by the Food and Drug Administration (FDA)
for medical use.38−41 PF127 is an amphiphilic polymer
consisting of hydrophilic polyethylene glycol (PEG) blocks
and more-hydrophobic polypropylene glycol (PPG) blocks.35
The PNIPAM-B is a thermally responsive polymer with a lower
critical solution temperature (LCST) of 14−16 °C, which
means the polymer is insoluble in water (hydrophobic) at room
temperature (∼22 °C), while it is highly soluble in water
(hydrophilic) at or below 14 °C.42 DPPC is used to improve
the biocompatibility of the nanoparticles.43,44 First, aqueous
solution containing DOX was emulsified with organic solvent
containing PF127, PNIPAM-B, and DPPC. This leads to the
formation of a water-in-oil structure to encapsulate DOX in the
hydrophilic core dispersed in organic solvent (Figure 1a). For
second emulsion, the product of the first emulsion is emulsified
with the aqueous solution of chitosan-PF127 and HA. The
hydrophobic part of chitosan-PF127 could integrate into the
hydrophobic inner layer, while the hydrophilic part of chitosan-
PF127 could bind with HA at the outermost layer of the
resultant nanoparticles.43,45 The reason to decorate HA on the
surface of the nanoparticles is that HA is a natural ligand of the
variant CD44 commonly overexpressed on many types of
cancer cells and particularly CSCs.46−48 Therefore, the surface
of the nanoparticles consists mainly of PEG and HA, which
makes the nanoparticles highly dispersible in aqueous solutions
as both PEG and HA are hydrophilic. The nanoparticles can be
collected by centrifugation after removing organic solvent by
rotary evaporation under a vacuum.
Typical transmission electron microscopy (TEM) image of
the resultant nanoparticles (HCLPN-D, H for HA, C for
chitosan, L for the lipid DPPC, P for PF127, N for PNIPAM-B,
and D for DOX) is shown in Figure 1b. The nanoparticles are
∼100 nm in diameter with a spherical morphology, and
interestingly, they have a multicore−shell structure. The
multicore−shell structure is probably mainly due to the
presence of lipid during the first emulsion when the lipid
together with PNIPAM-B and PF127 may form small sized
water-in-oil (W-in-O) structures. A few of them together may
form the final nanoparticles after the second (W-in-O)-in-W
emulsion. This is because the multicore−shell structure is not
obvious for nanoparticles prepared in the same way without
lipid (Figure S1). Moreover, few nanoparticles could be
collected by centrifugation if PF127 and DPPC (PF127 +
DPPC) were used for synthesizing nanoparticles using the
same procedure (Figure S2a). Although more nanoparticles
could be collected if PNIPAM-B and DPPC (PNIPAM-B
+DPPC) were used, the drug encapsulation efficiency (EE) is
lower than that of HCLPN nanoparticles (Figure S2b, 4.7 ±
2.5% for PF127 + DPPC, 14.5 ± 2.2% for PNIPAM-B+DPPC,
and 59.7 ± 4.3% for HCLPN nanoparticles). This can be
confirmed visually by the redness (the color of DOX) of the
three different samples after removing nonencapsulated DOX
by centrifugation and resuspending in deionized (DI) water
(Figure S3a). When a red laser beam was shined through the
three samples, the light track is weak in the PF127 + DPPC
sample while it is evident in the PNIPAM-B + DPPC and
HCLPN-D samples (Figure S3b) as a result of the Tyndall
effect due to light scattering by nanoparticles. The TEM image
of the PF127+DPPC sample shows that most of the DPPC
form liposomes during the preparing process (Figure S3c).
Although core−shell nanoparticles are formed in the PNIPAM-
B + DPPC sample, their size is not uniform, and some can be as
big as ∼400 nm in diameter (Figure S3d).
Cold-Responsiveness of HCLPN-D Nanoparticles. We
next investigated the cold-responsive property of the HCLPN-
D nanoparticles. As aforementioned, the PNIPAM-B polymer
for making the nanoparticles is hydrophobic at room
temperature and has an LCST of 14−16 °C. Once the
temperature is lower than the LCST, the PNIPAM-B polymer
becomes water-soluble. This may cause disassembly of the
nanoparticles in aqueous solutions (Figure 1c). Indeed, almost
all the HCLPN-D nanoparticles were disassembled after
incubating at 10 °C for 3 min (Figure 1d). Extensive polymer
aggregates formed when the temperature was increased back to
room temperature (22 °C, Figure 1e). This is further confirmed
by shining a red laser beam through the aqueous samples of the
HCLPN-D nanoparticles at different temperatures. A light track
in the sample indicates the presence of nanoparticles. As shown
in Figure 1f, the aqueous solution of the nanoparticles appears
homogeneous at both 37 and 22 °C before cooling. This is
attributed to the high dispensability of the nanoparticles in
aqueous solutions. When the temperature decreases to 10 or 6
°C, the solution of HCLPN-D nanoparticles becomes trans-
parent, and no evident light track could be observed, suggesting
disassembly of the nanoparticles and dissolution of polymers in
the nanoparticles in the aqueous solution. More importantly,
many visible polymer aggregates formed when the temperature
was increased back to room or body temperatures (22 and 37
°C respectively, Figure 1f), suggesting the disassembly is
irreversible. We further checked the size distribution of
HCLPN-D nanoparticles at different temperatures by dynamic
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light scattering (DLS). The HCLPN-D nanoparticles have a
narrow size distribution with one single peak at temperatures of
37, 22, and 15 °C (82.3 ± 4.6, 96.7 ± 3.4, and 110.3 ± 2.5 nm
in diameter, respectively), but a second peak of much larger
particles/aggregates appears at 12 °C (Figure 1g). Moreover,
no stable measurement could be made at 10 and 6 °C, probably
because nearly all the nanoparticles are dissembled at the cold
temperatures. The stability of HCLPN-D nanoparticles in
acidic solution (pH 6.5) was further checked as the tumor
microenvironment is often acidic with a pH value of ∼6.5.49 As
shown in Figure S4, the size distribution measured by DLS
suggested the HCLPN-D nanoparticles are stable at pH 6.5.
However, the nanoparticles are not stable at pH 5.0 (the pH
value of late endosomes and lysosomes) as their size increases
and even form some aggregates of ∼2.5 μm in pH 5.0 solution.
Lastly, the HCLPN-D nanoparticles are stable at room
temperature for at least 49 days according to the DLS size
analyses (Figure S5).
We further checked the ultraviolet−visible (UV−vis)
absorbance of the HCLPN-D nanoparticles at different
temperatures. As shown in Figure 2a, the absorbance peak
(arrow) of DOX at 486 nm is not obvious at or above 12 °C
due to the strong absorbance of the HCLPN nanoparticles at
the same wavelength. However, it shows up more clearly at 10
or 6 °C because of dissolution of polymers in the nanoparticles.
When the temperature increased back to 22 °C, the absorbance
is strong at all wavelength. This suggests the polymer
aggregates may block the light to result in the strong
absorbance. To confirm this, the drug release profile of
HCLPN-D nanoparticles was determined by using ice to cool
the samples. The drug release from HCLPN nanoparticles is
slow at 37 °C (∼2.2% in 5 h), while more than 70% of DOX
can be released from the nanoparticles after cooling on ice for 5
min (Figure 2b). In contrast, the drug release is less than 5% if
the nanoparticles are kept at low pH (5.0) for 5 min. These
drug release data indicate that cold is an effective stimulus for
triggering drug release from the HCLPN nanoparticles, and it is
much more efficient than pH excursion.
Overcoming Drug Resistance and Cancer Targeting in
Vitro. Both two-dimensional (2D) cultured NCI/RES-ADR
multidrug-resistant cancer cells and three-dimensional (3D)-
cultured CSC-enriched spheres (obtained by suspension
culture of the NCI/RES-ADR cells in CSC medium in ultralow
attachment plates) were used in this study. We confirmed the
resistance to free DOX of the 2D cultured NCI/RES-ADR cells
by incubating the cells with free DOX (10 μg/mL) for 3 h. As
shown in the first row of Figures 3a and S6, no red fluorescence
of DOX is observable in the 2D cultured NCI/RES-ADR cells.
In stark contrast, red fluorescence of DOX is observable in the
cells when they are incubated with the HCLPN-D nano-
particles (Figures 3a and S7). However, DOX is predominantly
distributed in the cytosol, and it is barely observable in the
nuclei of the NCI/RES-ADR cells incubated with the HCLPN-
D nanoparticles. Since DOX has to enter the nuclei for
cytotoxicity, the data suggest that simply using nanoparticles for
uncontrolled drug release may not be able to efficiently
overcome the drug resistance of the NCI/RES-ADR cells. To
check if cold-triggered burst drug release could overcome the
drug resistance, the cells treated with free DOX or HCLPN-D
nanoparticles for 3 h were further cooled with ice for 5 or 10
min. For the cells treated with free DOX, the red fluorescence
is still not observable (Figure 3a and Figure S6). Interestingly,
DOX is located in part of the nuclei of the cells treated with
HCLPN-D nanoparticles after cooling for 5 min, and DOX
overlaps with nearly all the nuclei after 10 min of cooling
(Figure 3a and Figure S7). In contrast, almost all DOX is still
distributed in the cytosol if the cells are continuously cultured
at 37 °C, indicating the cold-triggered burst drug release indeed
can overcome the drug-resistant capacity of the NCI/RES-ADR
cancer cells.
In order to confirm the temperature drop to below 12 °C in
the cells with ice cooling, FLIR (Wilsonville, Oregon, USA)
near-infrared thermography was used to determine the
temperature of the samples. As illustrated in Figure S8, the
temperature of samples treated with free DOX or HCLPN-D
nanoparticles is ∼37 °C in incubator, decreases to ∼4−0 °C
(within ∼3 min) after ice cooling for 5 or 10 min, and returns
Figure 2. Cold-triggered burst drug release from HCLPN-D nanoparticles. (a) UV−vis absorbance of HCLPN-D nanoparticles at different
temperatures showing the cold-responsiveness of HCLPN-D nanoparticles. Arrows indicate the absorbance peaks of DOX. (b) A comparison of the
release of DOX from HCLPN-D nanoparticles under pH 7.4, acidic pH (5.0, 5 min), and ice cooling (5 min), showing the cold temperature is much
more effective than low pH in triggering drug release from the HCLPN-D nanoparticles. Error bars represent ± standard deviation (SD, n = 3).
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to ∼37 °C after warming in incubator for 5 min. This is
consistent with the medium temperature in the sample
measured with thermocouples (Figure S9).
It is also noticeable that the overall fluorescence intensity of
DOX inside cells after ice cooling increases compared with cells
kept at 37 °C, probably due to the following three reasons.
First, the fluorescence intensity of DOX decreases after
encapsulated inside the nanoparticles due to self-quenching
(Figure S10). After ice cooling, the free DOX released from the
HCLPN-D nanoparticles results in higher fluorescence
intensity. Second, the fluorescence intensity of DOX decreases
slightly in acidic solution (Figure S10). HCLPN-D nano-
particles are taken up by cells via endocytosis and locate inside
the endo-/lysosomes (pH ≈ 5.0). The fluorescence intensity of
DOX should increase after the DOX is released from the
nanoparticles and enter the nuclei with a pH value of ∼7.0.
Third, the high binding affinity of DOX with cell nuclei may
lead to accumulation of DOX in the cell nuclei, which should
result in increased fluorescence.50
CSC-enriched spheres were also treated in the same way as
that aforementioned for 2D cultured cells. Similarly, the CSC-
enriched spheres are resistant to free DOX, but can take up the
HCLPN-D nanoparticles (Figures S11 and 3b). Importantly,
most of the DOX can enter the cell nuclei after cooling the
spheres with ice for 5 or 10 min. Further quantitative analyses
show that the intensity of DOX in cell nuclei is significantly
increased after ice-cooling (Figure S12). Next, we investigated
the cellular uptake of different concentration (5, 10, and 25 μg/
mL) of free DOX or HCLPN-D nanoparticles with or without
ice cooling for 10 min. As shown in Figures S13−16 (Figures
S13−14 for free DOX and Figures S15−16 for HCLPN-D
nanoparticles), no red fluorescence of DOX is observable in the
multidrug-resistant cells treated with free DOX, while more
DOX could be observed in cells treated with high concentration
Figure 3. Overcoming cancer drug resistance with cold-triggered burst drug release form HCLPN-D nanoparticles. (a) Confocal micrographs of 2D
cultured NCI/RES-ADR multidrug-resistant cancer cells after incubating them with either free DOX or HCLPN-D nanoparticles for 3 h at 37 °C,
followed by either continued culturing in incubator (37 °C) or ice cooling (+I) for 5 or 10 min. (b) Confocal images of CSC-enriched spheres
derived from the multidrug-resistant cancer cells after incubating them with HCLPN-D nanoparticles for 3 h at 37 °C, followed by either continued
culturing in incubator (37 °C) or ice cooling (+I) for 5 or 10 min. DOX could enter the cell nuclei only when treated with both HCLPN-D
nanoparticles and ice cooling, indicating the cold-triggered burst drug release from the HCLPN-D nanoparticles could be used to overcome the drug
resistance of the 2D cultured cancer cells and their CSCs.
ACS Central Science Research Article
DOI: 10.1021/acscentsci.8b00050
ACS Cent. Sci. 2018, 4, 567−581
571
of HCLPN-D nanoparticles. After ice cooling, stronger
fluorescence is observable in the cells treated with HCLPN-D
nanoparticles, particularly at high concentrations. This is not
observable for free DOX treated cells. Similarly, quantitative
analysis of DOX in the cell nuclei reveals that cells treated with
HCLPN-D nanoparticles and ice cooling have higher DOX
concentration in their nuclei (Figure S17). Since the pH value
of the tumor microenvironment is ∼6.5, we checked the
capacity of overcoming drug resistance by the HCLPN-D
nanoparticles at pH 6.5. As shown in Figure S18, most of the
DOX released from the HCLPN-D nanoparticles as a result of
ice cooling enters the nuclei of cancer cells both under 2D
culture and in CSC-enriched spheres, suggesting the HCLPN-
D nanoparticles can still be used to overcome cancer drug
resistance in the acidic tumor microenvironment.
As the HA modified on the surface of HCLPN-D
nanoparticles is used to target CD44, we first studied the
expression of CD44 on the 2D cultured NCI/RES-ADR cells
and cells in the CSC-enriched spheres by using flow cytometry.
As shown in Figure S19a,b, the expression of CD44 on the
NCI/RES-ADR cells is positive, and it is similar to that on
MDA-MB-231 cancer cells that are considered as CD44
positive.51,52 Moreover, the expression of CD44 on cells in
the CSC-enriched spheres is significantly higher than that on
the 2D cultured NCI/RES-ADR cells, suggesting the HCLPN-
D nanoparticles can be used for targeting both the drug-
Figure 4. Enhanced in vitro anticancer capacity by HCLPN-D nanoparticles with ice cooling for overcoming drug resistance. Viability of (a) 2D
cultured NCI/RES-ADR multidrug-resistant cancer cells and (b) CSC-enriched spheres derived from the multidrug-resistant cancer cells after
treating them with blank nanoparticles (HCLPN), free DOX, and HCLPN-D nanoparticles without or with ice cooling for 5 or 10 min. The viability
of control cells cultured in pure medium is 100%. Error bars represent SD (n = 3). *: p < 0.05 (Kruskal−Wallis H test), which indicates cells treated
with HCLPN-D nanoparticles and ice cooling for 10 min is significantly lower than other treatments with the same drug concentration. (c) TEM
images of the NCI/RES-ADR cancer cells treated with saline, HCLPN-D nanoparticles with or without ice cooling for 10 min. The endo-/lysosomes
in HCLPN-D treated cells light up due to the existence of intact (without ice cooling) or disassembled (with ice cooling) HCLPN-D nanoparticles.
The insets are the endo-/lysosomes indicated by the arrows with either intact or disassembled HCPN-CG nanoparticles. (d) A schematic illustration
of the combination of the HCLPN-D nanoparticle and ice cooling for overcoming the multidrug resistance to enhance cancer destruction, in
comparison to the HCLPN-D nanoparticle alone and free drug. The combination can overcome the drug resistance in cancer cells by (1) cold-
triggered burst drug release from the HCLPN-D nanoparticles and (2) the cold-induced low activity of the membrane transporters to pump out the
released drug.
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resistant cancer cells and their CSCs. The data also
demonstrate that CSCs are enriched in the 3D cultured
NCI/RES-ADR spheres because CD44 is a common CSC
marker.47,48,53 Furthermore, the binding between the nano-
particles with HA on their surface and CD44 is confirmed using
confocal fluorescence microscopy. As shown in Figure S20,
most of the CD44 in control group is located on the surface of
the cell membrane. Moreover, many of them are internalized
into the cytoplasm after incubated with the HCLPN-D
nanoparticles, suggesting the nanoparticles bind with CD44
and are then taken up by the cells. Interestingly, some line
structures with CD44 are observable after ice cooling. This is
probably because polymers bound with CD44 on the surface of
the HCLPN-D nanoparticles could form fibers after cooling-
induced disassembly of the nanoparticles (Figure 1e). The
targeting capability of HCLPN-D nanoparticles was further
confirmed by treating the drug resistance cells using nano-
particles without HA modification on their surface (LPN-D).
As shown in Figure S21a, more DOX could be delivered inside
the cells with HCLPN than LPN nanoparticles due to the
targeting capability of HA on the HCLPN nanoparticles.
Therefore, after cooling with ice, the HCLPN-D nanoparticles
can be used to deliver more DOX into the nuclei than LPN-D
nanoparticles (Figure S21b).
Enhanced Anticancer Capacity in Vitro via Over-
coming Drug Resistance. To investigate the anticancer
capacity of HCLPN-D nanoparticles, both the 2D drug-
resistant cancer cells and 3D CSC-enriched spheres were
treated with HCLPN nanoparticles (without DOX), free DOX,
and HCLPN-D nanoparticles at various concentrations without
or with ice (+I) cooling for 5 or 10 min. The total treatment
time for all the drug formulations is either 24 or 48 h. For
treatments with ice cooling, it was conducted after incubating
cells with the various formulations at 37 °C for 12 h, and the
cells were put back in 37 °C incubator after the cooling
treatment to further culture for 12 or 36 h. FLIR thermographs
indicate that cells cultured in a 96-well plate can be efficiently
cooled to ∼4−0 °C with ice for 5 or 10 min (Figure S22a),
which is consistent with the medium temperature in the sample
measured with thermocouples (Figure S22b). The safety of ice
treatment is confirmed by checking the viability of cells
incubated with ice for 5 or 10 min. As shown in Figure S23, the
ice treatment alone has no effects on the cell viability at both 24
and 48 h. According to the viability data of both 2D cultured
NCI/RES-ADR cells (Figure 4a) and CSC-enriched spheres
(Figure 4b), blank HCLPN nanoparticles with or without ice
cooling are also not harmful to the cells for both the 24 and 48-
h treatments. Interestingly, HCLPN-D nanoparticles show
higher cytotoxicity than free DOX only at high drug
concentrations (50, 25, and 10 μg/mL for 2D cells; 50 μg/
mL for CSC-enriched spheres, p < 0.05), probably due to the
capability of the membrane transporter to pump out drug
slowly released from the nanoparticles. However, the
cytotoxicity of DOX is not significantly affected if it is simply
mixed with blank HCLPN nanoparticles with or without ice
cooling. In addition, ice cooling for 10 min could further
significantly decrease the viability of 2D cells or spheres treated
with free DOX at 50 μg/mL (p < 0.05, for both 2D cultured
NCI/RES-ADR cells and CSC-enriched spheres). This is
probably due to the reduced activity of membrane transporters
in the cells cooled with ice for 10 min, which may allow some
free DOX to enter the cells treated with free DOX at the high
concentration. To confirm this, we further checked the uptake
of free DOX at high concentrations (50, 80, and 160 μg/mL)
under the same thermal treatments for obtaining the data in
Figure 3. As shown in Figure S24, although some free DOX
could enter the drug-resistant cells at 50 μg/mL, it is minimal in
the cell nuclei. This may explain the high viability of the cells
treated with 50 μg/mL free DOX (Figure 4a). The fluorescence
intensity gradually increases at higher drug concentrations.
Although ice cooling for 5 min does not seem to significantly
improve the intracellular DOX at all the three concentrations
(Figure S24), significantly more DOX could enter the cells with
ice cooling for 10 min. The latter is probably because the
membrane transporter activity of the cells is significantly
decreased after 10 min of ice cooling.
It is worth noting that most of the DOX remains in the
cytoplasm after entering the drug-resistant cells incubated with
the free DOX at the usually high concentrations, although free
DOX usually enter the nuclei of non-drug-resistant cancer cells.
This is further confirmed by incubating the cancer cells with
free DOX on ice for 1 h. As shown in Figure S25, more free
DOX could enter the cells compared to 5 or 10 min of ice
cooling (Figure 3a). This suggests cold could decrease the
activity of the efflux pump (i.e., temperature-dependent activity
of the pump), but it requires more than 10 min for the activity
to be sufficiently compromised for free DOX to enter the drug-
resistant cells. Nonetheless, most of the free DOX stays in the
cytoplasm after the 1 h of ice cooling, which is similar to the
observation after incubating the cells with free DOX at high
concentrations (50−160 μg/mL) on ice for 5−10 min (Figure
S24). This may explain the cell viability data shown in Figure
S26 because DOX must enter the cell nuclei to induce
cytotoxicity. Although the toxicity of free DOX at 160 μg/mL
to the drug-resistant cells with 10 min of ice cooling is
significantly higher than that to the cells kept at 37 °C or with 5
min of ice cooling, more than 60% of the cells could still survive
at such an unusually high concentration. These observations
suggest the diffusion of free DOX through the plasma
membrane into the drug-resistant cells may activate some
protective mechanism to prevent the drug from entering the
nuclei, in addition to trying to pump out the free drug with the
membrane transporters.
In stark contrast, the cytotoxicity of HCLPN-D nanoparticles
can be significantly enhanced after ice cooling (particularly for
10 min) at both low and high concentrations (Figure 4a,b),
which is in accordance with the data on cellular uptake and
DOX distribution in the cells (Figures 3 and S12). A higher
cytotoxicity (∼40 versus ∼60%) could be achieved by using
HCLPN-D+I (10 min) treatment with very low drug
concentration compared with free DOX treatment (32 times
lower, 5 versus 160 μg/mL). The cold-responsive capacity of
HCLPN-D nanoparticles inside cells is further confirmed by
cell TEM imaging. As shown in Figure 4c, although endo-/
lysosomes are not easily identifiable in saline treated cells, they
are lit up as white dots in cancer cells treated with the HCLPN-
D nanoparticles. This is probably a result of the white core−
shell structure of the nanoparticles under TEM (Figure 1b).
Moreover, almost all the HCLPN-D nanoparticles in the
endo-/lysosomes become disassembled after ice cooling,
suggesting the cold-responsive capacity of the HCLPN-D
nanoparticles retains inside cells. It is worth noting that
disassembly of HCLPN-D nanoparticles with ice cooling
partially disrupts the structure of endo-/lysosomes according
to the TEM images. This could facilitate the DOX released
from the nanoparticles to further escape from the endo-/
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lysosomes into the cytoplasm. These data indicate that the
aforementioned challenges associated with free DOX can be
efficiently resolved by using the cold-responsive HCLPN-D
nanoparticles for intracellular delivery of the drug (Figures 3
and 4).
We also incubated both 2D cultured cells and 3D CSC-
enriched spheres with free DOX and loperamide, a substrate of
P-gp and can be used as the P-gp inhibitor.54 As shown in
Figure S27, by mixing with P-gp inhibitor, free DOX indeed is
significantly more toxic than the free drug alone (Figure 4a) to
the 2D cultured cells after 24 h of incubation, and the
cytotoxicity further increases at 48 h. For 3D CSC-enriched
spheres, free DOX mixed with loperamide shows higher
cytotoxicity than the free drug alone (see Figure 4b) only after
48 h of incubation. Moreover, the overall cytotoxicity of free
DOX mixed with loperamide is still less than that of HCLPN-D
nanoparticles with ice cooling (Figure 4a,b). This is probably
because most of the free DOX and sustained/slowly released
DOX from HCLPN-D nanoparticles (without ice cooling) may
still stay in the cytoplasm after entering the cancer cells in the
presence of loperamide to block the efflux pump. This
hypothesis is confirmed with confocal images of cells treated
with free DOX and HCLPN-D nanoparticles in the absence or
presence of loperamide, as shown in Figure S28.
A schematic illustration of the combination of the HCLPN-D
nanoparticles and ice cooling for overcoming the drug
resistance to enhance cancer destruction, in comparison to
the HCLPN-D nanoparticle alone and free drug, is given in
Figure 4d. Free drug can be quickly pumped out of cells after its
diffusion into cells due to its close proximity to the membrane
transporters (or immobilized in the cytoplasm by possible
additional mechanism when the drug concentration is unusually
high). Using nanoparticles alone for slow drug release, the
nanoparticles may be taken up by cancer cells via CD44
receptor-mediated endocytosis (Figure S20), which may also be
mediated by clathrin or caveolin.55,56 However, most of the
slowly released drug may be still pumped out of the cells before
it binds with its targets in the cells. This is because the activity
of transmembrane transporters is intact, and the concentration
of drug in cells is not high enough to outperform the pumping
capacity of the transporters. Importantly, the HCLPN-D
nanoparticles could quickly disassemble to release most of
the encapsulated drug when cooled with ice and disrupt the
structure of endo/lysosomes. Due to its small size, the released
free DOX can diffuse out of the damaged endo-/lysosomes
driven by its concentration gradient without the need of any
metabolic energy. Although some of the released drug may be
pumped out of cells during the cooling process, most of the
drug can enter and bind with the nuclei due to the burst
release-induced high drug concentration in the cytoplasm and
the compromised pumping capacity of the transporters at cold
temperature (Figure 4d).
In Vivo Tumor Targeting and Enhanced Capacity of
Destroying Drug Resistant Tumors. Next, we investigated
the biodistribution of the HCLPN nanoparticles in drug-
resistant tumor-bearing mice by encapsulating indocyanine
green (ICG or G) to obtain ICG-laden nanoparticles (HCLPN-
G). Tumors were produced by subcutaneous injection into the
upper hindlimb of 20, 000 CSC-enriched sphere cells per
animal (7 week-old female nude mouse). As shown in Figure
5a, the ICG fluorescence was detectable over almost the whole
animal body for both HCLPN nanoparticles and free ICG at 1
h after intravenous injection. More importantly, the HCLPN-G
nanoparticles treated mice have stronger fluorescence in their
tumors, suggesting preferential accumulation of the HCLPN
nanoparticles in the tumors. The accumulation of HCLPN-G
nanoparticles in tumor further increases after 3 and 6 h of
injection. In contrast, the fluorescence in free ICG-treated mice
decreases at 3 h and almost disappears at 6 h after injection
(Figure 5a). To confirm the observations from whole animal
Figure 5. In vivo tumor targeting capacity of HCLPN-D nanoparticles. (a) In vivo whole animal imaging of ICG fluorescence at different times after
intravenous injection of free ICG and ICG-laden HCLPN-G nanoparticles via the tail vein. Arrows indicate the locations of tumors in mice. (b) Ex
vivo imaging of ICG fluorescence in tumor and five critical organs collected after sacrificing the mice at 9 h. (c) Imaging of total ICG fluorescence of
free ICG and ICG-laden HCLPN-G nanoparticles in three samples prepared in the same way as the solutions used for injection into mice. The
images were taken under the same condition as that for both the in vivo and ex vivo imaging. (d) Quantitative analysis of the distribution of HCLPN-
G and free ICG in tumor and five critical organs collected from free ICG and HCLPN-D nanoparticles treated mice. The data show that the
HCLPN-G nanoparticles could accumulate in tumor much more efficiently than free ICG. NCI/RES-ADR cells detached (with trypsin) from CSC-
enriched spheres were used to obtain xenografts of multidrug-resistant tumors for imaging.
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imaging, various organs were harvested for ex vivo imaging to
check the distribution of ICG fluorescence after sacrificing the
mice at 9 h. As shown in Figure 5b, only the tumors from mice
treated with HCLPN-G nanoparticles has ICG fluorescence
with an exposure time of 3 s, which is consistent with the
whole-animal imaging data. This is probably due to the
enhanced permeability and retention (EPR) effect of tumor
vasculature compared to that of normal organs, together with
the capability of HA on the surface of the HCLPN-D
nanoparticles in targeting CD44 overexpressed on the cancer
cells and CSCs.57,58
To quantify the biodistribution of ICG fluorescence in the
various organs including tumors, the total ICG fluorescence of
free ICG and ICG-laden HCLPN-G nanoparticles used for
injection into each mouse were obtained. This was done by
diluting the 100 μL of free ICG and ICG-laden HCLPN-G
nanoparticles (prepared in the same way as the 100 μL of
samples used for injection into each mouse) into 400 μL (to
prevent fluorescence overflow) in a centrifuge tube and imaging
in the same way as that for both in vivo and ex vivo imaging.
This experiment was conducted in triplicates (Figure 5c).
Interestingly, the average total fluorescence of HCLPN-G
nanoparticles used for injection into each animal is ∼99% of
that of free ICG, indicating minimal quenching of the ICG
fluorescence in the nanoparticles. The total fluorescence in each
organ shown in Figure 5b was subtracted with the total
fluorescence of the corresponding organ from the saline group
(to correct any auto fluorescence from tissue). The corrected
total fluorescence of ICG in each organ from the free ICG (or
HCLPN-G nanoparticles) group shown in Figure 5b was then
divided by the average total fluorescence of free ICG (or
HCLPN-G nanoparticles) used for injection into each animal
Figure 6. In vivo antitumor capacity of HCLPN-D nanoparticles with ice cooling studied using subcutaneous tumor model. (a) Near infrared
thermographs of whole animal and human hand before and after ice cooling for 10 min (+I), showing temperature in the region with cooling can be
effectively decreased to ∼0 °C. (b) Typical photographs showing the size of tumors (indicated by arrows) on day 59 in mice with six different
treatments. (c) Tumor growth curves for the six different treatments. Error bars represent SD (n = 5). The red arrow heads indicate the times of
conducting injections. *: p < 0.05, **: p < 0.01 (Kruskal−Wallis H test). (d) Weight of the tumors collected after sacrificing the mice on day 59.
Error bars represent SD (n = 5). **: p < 0.01 (Kruskal−Wallis H test). (e) Representative histology (H&E) images of the tumors collected on day
59. The HCLPN-D+I treated tumors are more necrotic than tumors with the other five treatments. (f) Immunofluorescent staining of CD44 and
CD133 in tumor showing diminished expression of both CD44 and CD133 after the treatment with HCLPN-D+I. (g) Body weight and (h)
representative micrographs of H&E staining of four important organs with various treatments showing the minimized systemic toxicity of HCLPN-D
+I compared to treatments with free DOX (DOX and DOX+I).
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(Figure 5c) and averaged, to obtain the percentage of ICG
distribution in each organ. As shown in Figure 5d, the
accumulation of ICG in tumors is significantly improved by
∼50 times (∼15% versus ∼0.3%) with the nanoparticle
encapsulation. This further confirms the observations from
the qualitative in vivo and ex vivo imaging.
Lastly, we treated the drug-resistant tumor-bearing mice with
different drug formulations to understand the safety and
efficacy of the HCLPN-D nanoparticles in combination with 10
min of ice cooling for overcoming cancer drug resistance. To
assess the cooling effect in vivo, ice was applied through the skin
over the tumor area. FLIR near-infrared thermography was
used to determine the temperature immediately after ice
cooling (Figure 6a). After 10 min of cooling, the temperature in
the tumor area decreases to 4−7 °C. The ice cooling treatment
is also efficient on human (hand, Figure 6a). The drug-resistant
tumor-bearing mice were randomly divided into six groups:
saline, blank nanoparticles (HCLPN), free DOX without or
with ice cooling (DOX or DOX+I), and HCLPN-D nano-
particles without or with ice treatment (HCLPN-D or HCLPN-
D+I). Mice were treated with the various formations at a total
DOX dose of 3 mg/kg body weight via intravenous injection
when the tumor reached ∼100 mm3 on day 1, 8, 15, 22, and 29.
After 12 h of each of the injections, tumors were cooled with
ice for 10 min. No mice died during the course of the 59 days
of treatment and observation.
As shown in Figure 6b,c, tumor growth for treatments with
blank HCLPN nanoparticles and free DOX is similar to that of
saline control. This is not surprising as the tumors are
generated with multidrug-resistant and CSC-enriched cancer
cells. In addition, ice cooling does not affect the antitumor
ability of free DOX. The tumor volume for the treatment with
HCLPN-D is slightly reduced compared to saline control
although the difference is not significant. Importantly, the
HCLPN-D nanoparticles with ice cooling (HCLPN-D+I)
exhibit excellent antitumor capacity and significantly inhibit
the tumor growth compared to all the other five treatments.
The size and weight of the tumors for the HCLPN-D+I
treatment are significantly less than that from all the other five
treatments (Figure 6d and Figure S29). Moreover, histological
Figure 7. In vivo antitumor capacity of HCLPN-D nanoparticles with ice cooling studied using orthotopic metastasis model of ovarian cancer. (a)
Near infrared thermographs of whole animal on the ventral side before and after ice cooling for 10 min. The data show that temperature on the skin
with cooling on the ventral side of the peritoneal cavity can be effectively decreased to ∼6−10 °C. (b) Photographs showing the typical in situ
locations of tumors (indicated by arrows and circles) from mice treated with saline and free DOX. (c) Photograph showing the size of tumors
collected after sacrificing the mice on day 32 with three different treatments. (d) Weight of the tumors collected on day 32. Error bars represent SD
(n = 3). (e) Representative histology (H&E) images of the tumors collected on day 32. (f−g) Body weight (f) and representative micrographs of
H&E staining of five critical organs (g) with various treatments. The data show reduced systemic toxicity of the treatment of HCLPN-D
nanoparticles with ice cooling for 10 min (HCLPN-D+I) compared with the free DOX+I treatment. *: p < 0.05 (Kruskal−Wallis H test).
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examination (hematoxylin&eosin or H&E stain) reveals
extensive necrosis in the tumors from the HCLPN-D+I
treatment group while tumors from all the other groups are
more viable (Figure 6e and Figure S30).
CD44 and CD133 are two surface markers involved in many
cell functions and believed to be associated with tumor-
igenicity.47,48,53 Both have been commonly used as the surface
markers of various CSCs.47,48,53 We checked the expression of
both markers in 2D cultured NCI/RES-ADR cells and 3D-
cultured CSC-enriched spheres first. As shown in Figures S31
(for 2D cultured NCI/RES-ADR cells) and S32 (for the CSC-
enriched spheres), the expression of CD44 and CD133 in the
CSC-enriched spheres is increased compared with 2D cultured
NCI/RES-ADR cells. After treatment with HCLPN-D nano-
particles for 12 h without ice cooling, the expression of CD44
and CD 133 is decreased only slightly. Importantly, after ice
cooling and further incubation for 12 h at 37 °C, the expression
of both markers is minimized in both 2D cultured NCI/RES-
ADR cells and 3D cultured CSC-enriched spheres (Figure
S31−32). In order to check the anti-CSC ability of the
HCLPN-D nanoparticles with 10 min of ice cooling in vivo, the
expression of the variant CD44 and CD133 was further studied
in the in vivo tumors after the various treatments. Typical
micrographs of immunofluorescent staining of the two CSC
markers are shown in Figure 6f. The expression of the two
markers in tumors treated with saline, HCLPN nanoparticles,
DOX, DOX+I, and HCLPN-D nanoparticles is high. In
contrast, their expression in tumors with the HCLPN-D+I
treatment is negligible. These observations from the immuno-
fluorescent staining were further confirmed by immunohisto-
chemistry staining of the two markers in tumors from the
various treatments (Figure S33), which suggests that the
HCLPN-D nanoparticles combined with 10 min of ice cooling
are effective to kill the CSCs in vivo. Collectively, these data
demonstrate the enhanced in vivo antitumor efficacy of the
HCLPN-D nanoparticles combined with ice cooling.
Equally important, we did not notice any obvious sign of side
effects for the HCLPN-D+I treatment. Although during the ice
treatment, normal tissue around tumor might be affected by ice
cooling and DOX released from nanoparticles, neither death
nor significant drop of body weight was noted for saline,
HCLPN nanoparticles, HCLPN-D, and HCLPN-D+I treat-
ments (Figure 6g). In contrast, the body weight of mice treated
with free DOX and DOX+I were significantly reduced during
the treatments, indicating significant systemic toxicity of the
treatments with the free drug. To further confirm this, various
critical organs including liver, kidney, heart, and lung from
saline, DOX, and HCLPN-D+I treatments were harvested,
fixed, and assessed by histology (H&E stain). As shown in
Figure 6h and Figure S34, free DOX treatment results in
hepatic damage including macro- and microvesicular steatosis
and bile stasis. Slight nephrotoxicity and cellular damage
(vacuolization) of cardiac muscle were also observable for the
free DOX treatment. Severe pulmonary damage with markedly
reduced alveolar surface area (honeycomb lung) was obvious in
the lung of mice with free DOX treatment. However, no
obvious damage to these organs was observable in the H&E
stained tissue slices for the mice with HCLPN-D+I treatment
(Figure 6h and Figure S34).
In order to further confirm the antitumor capacity and safety
of the HCLPN-D nanoparticles with ice cooling, an orthotopic
metastasis model of ovarian cancer was established by
intraperitoneal injection of the NCI/RES-ADR cells into the
peritoneal cavity of mice. The mice were then treated with
saline, free DOX, and HCLPN-D nanoparticles at a total DOX
dose of 3 mg/kg body weight via intraperitoneal injection on
Figure 8. A Schematic illustration of overcoming drug resistance with HCLPN-D nanoparticles and ice cooling for enhanced cancer therapy. In vivo
accumulation of HCLPN-D nanoparticles in tumor through the enhanced permeability and retention (EPR) effect of tumor vasculature could
minimize the side effects associated with free DOX. Moreover, the HCLPN-D nanoparticles can specifically target cancer stem cells (CSCs) via the
HA-CD44 interaction to facilitate their uptake by the CSCs. Although drug slowly released from nanoparticles at 37 °C (or mild hyperthermic
temperatures) could be still pumped out of the multidrug-resistant cancer cells, the cold-triggered burst drug release together with the compromised
pumping activity of membrane transporters in the multidrug-resistant cancer cells under cold temperature could efficiently overcome their drug-
resistant capacity. As a result, the cold-responsive nanoparticle in combination with ice cooling could efficiently inhibit the growth of multidrug-
resistant tumor in vivo.
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day 7, 14, and 21. After 12 h of each of the injections, tumors
(if any) were cooled by applying ice for 10 min on the skin
outside the peritoneal cavity on the ventral side. As shown in
Figure 7a, the temperature decreased to 6−10 °C at the ice
treated area after the 10 min of ice cooling. All the mice were
sacrificed on day 32, and tumors can only be found in the saline
and free DOX treated mice (Figure 7b-d). The tumors are
further confirmed by H&E staining data (Figure 7e). This is
not surprising as the NCI/RES-ADR cells are resistant to free
DOX, which can be overcome by using HCLPN-D nano-
particles with ice cooling. The body weight of mice treated with
free DOX is also reduced and significantly different from that of
mice in the saline and HCLPN-D groups on day 21 (Figure 7f).
H&E staining of various critical organs (kidney, spleen, liver,
heart, and lung) indicates that the free DOX treatment causes
severe kidney injury together with some hepatic and cardiac
damage (Figure 7g and Figure S35). The severe renal injury
may be because of the intraperitoneal injection free DOX that
could diffuse into the organ. Importantly, these side effects of
free DOX can be minimized by encapsulating the drug inside
HCLPN nanoparticles for delivery via intraperitoneal injection.
To further support this, we incubated noncancerous human
umbilical vein endothelial cells (HUVECs) with both free DOX
and HCLPN-D nanoparticles. As shown in Figure S36, free
DOX can easily enter HUVECs but not the NCI/RES-ADR
cells (top panels). In contrast, uptake of HCLPN-D nano-
particles by the HUVECs is minimal compared to the NCI/
RES-ADR cells either without (middle panels) or with (bottom
panels) ice cooling. These data indicate the HCLPN nano-
particles are capable of not only significantly enhancing the
efficacy of DOX in destroying drug-resistant tumors when
combined with ice cooling, but also minimizing its systemic
toxicity via intraperitoneal or intravenous injection.
■ DISCUSSION
In this study, we developed a cold responsive nanoparticle for
overcoming the drug resistance of NCI/RES-ADR cells and
reducing the potential side effects associated with chemo-
therapy drug (DOX). As schematically illustrated in Figure 8,
there are two possible mechanisms for this strategy to
overcome cancer drug resistance. The first mechanism is the
ice cooling induced burst release of drug from the HCLPN-D
nanoparticles. As shown in Figure 2b, more than 70% of DOX
can be released from the HCLPN-D nanoparticles during ice
cooling for 5 min. The released free DOX can diffuse out of the
endo-/lysosomes driven by its concentration gradient without
the need of any metabolic energy. At the same time, the
structure of endo-/lysosomes may be damaged during the
disassembly of the HCLPN-D nanoparticles as a result of ice
cooling (Figure 4c), to further facilitate the escape of the
released DOX from the endo/lysosomes. With a large amount
of free DOX being released into cytoplasm in a short time, a
significant amount of free DOX could bind with its target
before being pumped out of the cells by the efflux pumps on
the cell membrane (Figures 3, S7, S12, S15−S18, S21, S31, and
S32). In contrast, only ∼2.2% of the drug encapsulated in the
nanoparticles could be released in 5 h at 37 °C (Figure 2b).
This slowly released drug from the nanoparticles could be easily
pumped out of the cells by the efflux pump before entering the
nuclei (Figures 3, S7, S12, S15−S18, S21, S31, and S32). This
mechanism is further supported by the cell viability data
showing that ice cooling could greatly and significantly improve
the toxicity of the HCLPN-D nanoparticles to the multidrug-
resistant NCI/RES-ADR cells (Figure 4a,b). The second
mechanism is that the activity of efflux pumps can be reduced
during the ice cooling process. This is supported by the data on
cell uptake of free DOX without and with ice cooling (Figures
S24 and S25) and the viability data of cells treated by free DOX
at high concentrations (50−160 μg/mL) without and with ice
cooling (Figures 4a,b and S26). These high concentrations of
DOX are relevant because the intracellular concentration of
DOX delivered with the HCLPN-D nanoparticles (extracellular
DOX: 10 μg/mL) could be this high according to the
intracellular fluorescence intensity of DOX (Figure S24 versus
Figure 3a). This mechanism is due to the minimized metabolic
activity of cells at ice-cold temperature to deprive the energy
supply to the efflux pumps that work against the concentration
gradient of the chemotherapy drug across the cell membrane
(i.e., the drug concentration outside the multidrug-resistant
cells is higher than that inside the cells). Furthermore, the
HCLPN-D nanoparticles could efficiently and selectively
accumulate in tumors compared with free drug (Figure 5),
which could carry the chemotherapy drug selectively into
tumor. This together with the minimal release of drug from the
nanoparticles in normal tissue (always at 37 °C, Figure 2b) can
reduce the potential side effects of chemotherapy drug to
normal organs in vivo (Figures 6 and 7). We tested this strategy
for overcoming cancer multidrug resistance using both the 2D
cultured NCI/RES-ADR multidrug-resistant cancer cells and
their spheres enriched with CSCs.
The aforementioned two mechanisms for overcoming cancer
drug resistance with the HCLPN-D nanoparticles and ice
cooling are further supported by data obtained with the drug-
resistant A2780ADR ovarian cancer cells. As shown in Figure
S37, no red fluorescence of DOX is observable in the
A2780ADR cells after incubating them with free DOX (10
μg/mL) at 37 °C for 3 h, followed by either continuously
incubating at 37 °C or cooling with ice for 10 min. In stark
contrast, red fluorescence of DOX is observable in the cells
incubated with the HCLPN-D nanoparticles (containing 10
μg/mL DOX) at 37 °C for 3 h, although the DOX fluorescence
is predominantly distributed in the cytosol. Importantly, DOX
is located in the nuclei of the cells treated with HCLPN-D
nanoparticles with 10 min of cooling with ice after the 3 h of
incubation at 37 °C, while almost all DOX is still distributed in
the cytosol if the cells are continuously cultured at 37 °C for 10
min more. Quantitative analyses indicate that the intensity of
DOX in the cell nuclei is significantly increased after ice
cooling, as shown in Figure S38. We further investigated the
cell viability of the A2780ADR cells treated with free DOX and
HCLPN-D nanoparticles with or without ice cooling for 10
min. As shown in Figure S39, the cytotoxicity of HCLPN-D
nanoparticles is significantly enhanced after ice cooling, which
is in accordance with the data on cellular uptake shown in
Figures S37 and S38 and discussed above. We also noticed that
ice cooling for 10 min could further significantly decrease the
viability of A2780ADR cells treated with free DOX at 50 μg/
mL (p < 0.05), which is consistent with the viability data of the
NCI/RES-ADR cells with the same treatment (Figure 4a). This
is probably due to the second mechanism via reducing the
activity of the membrane transporters, as aforementioned for
the NCI/RES-ADR cells (Figures S24−S26). This is further
confirmed by incubating the A2780ADR cells with free DOX
(10 μg/mL) on ice for 1 h. As shown in Figure S40, more free
DOX could enter the cells compared with 10 min of ice cooling
(Figure S37). This supports that ice cooling could decrease the
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activity of the efflux pump (i.e., temperature-dependent activity
of the pump), which could minimize the amount of drug
(burst-released from the HCLPN-D nanoparticles inside the
drug-resistant cells in response to ice cooling) to be pumped
out of the cells before it enters the cell nuclei.
Since the HCLPN-D nanoparticles disassemble at ∼10 °C,
and biological tissues and cells may become frozen (i.e., form
solid ice) with minimized diffusion coefficient for small
molecules including chemotherapy drugs below ∼0 °C, the
therapeutic temperature with the HCLPN-D nanoparticles for
burst drug release to destroy tumors is suggested to be ∼0−10
°C. This can be conveniently achieved by cooling with ice that
is readily available in nearly all clinic settings, without the need
of a complex refrigeration system to achieve subzero or freezing
temperatures. It is worth noting the HCLPN-D nanoparticles
are also applicable for applications requiring subzero temper-
atures. This is because they may disassemble to induce burst
drug release during cooling or warming between the subzero
temperatures and 37 °C (body temperature). In fact, the
temperature is not constant (i.e., decreases with time from 37
°C to ∼4−0 °C) during ice cooling in this study (Figures S8,
S9, and S22). Therefore, we compared the viability and DOX
distribution in cells treated with free DOX and HCLPN-D
nanoparticles under two conditions: at body temperature (37
°C) and with ice cooling to cold temperature (below 10 °C).
Our data show the combination of the HCLPN-D nano-
particles and ice cooling could overcome cancer resistance
(Figure 3) to effectively kill the multidrug-resistant cells in vitro
(Figure 4) and in vivo (Figures 6 and 7).
It is worth noting that the CSC-enriched spheres are derived
from NCI/RES-ADR cells and can be maintained only in in
vitro culture using ultra low attachment plate and CSC medium.
After injection in vivo, some of the cells from the spheres may
differentiate, and some of them may remain undifferentiated. In
other words, we have no control of the stemness of the cells
from the CSC-enriched spheres in vivo. Therefore, the
difference between NCI/RES-ADR cells and CSC-enriched
spheres with different treatments was studied in vitro, and
overall the CSC-enriched spheres are more resistant to drug
than 2D cultured NCI/RES-ADR cells (Figure 4a,b). In view of
the latter, we used cells from the CSC-enriched spheres to
produce tumors for our in vivo studies to investigate if the
HCLPN-D nanoparticles with ice cooling could overcome
cancer drug resistance in vivo. We do not intend to compare the
NCI/RES-ADR cells and CSC-enriched spheres in vivo since
we could not control the stemness of the cells in vivo.
We tested the strategy of overcoming cancer drug resistance
with the HCLPN-D nanoparticles and ice cooling using both
subcutaneous and orthotopic metastasis model of ovarian
cancer. For the orthotopic metastasis model, the cells from the
CSC-enriched spheres were injected into the peritoneal cavity
(where ovarian cancer cells usually metastasize to)59 of mice via
intraperitoneal injection. Consistent with the clinical practice of
treating ovarian cancer metastasis,60 we used intraperitoneal
injection to deliver the HCLPN-D nanoparticles for treating
the orthotopic metastasis model in this study. In other words,
the nanoparticles are delivered into the peritoneal cavity where
the tumors are. This may be the major factor that contributes to
the excellent therapeutic outcome of the treatment with the
HCLPN-D nanoparticles and ice cooling for the orthotopic
metastasis model (no tumor was identifiable, Figure 7c),
compared with the subcutaneous model (small tumors could be
seen, Figure S29). For the latter, the nanoparticles are injected
intravenously through the tail vein that is away from the
subcutaneous tumors and the nanoparticles are diluted in blood
before reaching the subcutaneous tumors.
In this study, the potential of the proposed strategy of using
the cold-responsive nanoparticles for overcoming cancer drug
resistance is demonstrated by ice cooling of subcutaneous and
intraperitoneal tumors in small animals. Admittedly, ice cooling
may be difficult to apply for tumors in deep internal organs
(e.g., kidney and liver). Nonetheless, catheters with lumens
perfused with cold saline have been widely used for local
delivery of cold into deep organs to achieve local hypothermia
with the aid of minimally invasive surgical technologies such as
thoracoscopy, laparoscopy, and endoscopy.61−63 Therefore, the
local delivery of cold required for the nanoparticle system
developed in this study is not a hurdle to its future potential
applications for destroying tumors in deep organs. Since
techniques using cold and freezing temperatures have been
widely studied and used for treating various diseases including
cancer in the clinic (known as cryosurgery, cryotherapy,
cryoablation, and hypothermia),28−34 our cold responsive
nanoparticle-mediated drug delivery may be combined with
these techniques to further improve their safety and efficacy of
treating various diseases including cancer.
■ CONCLUSIONS
We developed a cold-responsive hybrid HCLPN-D nano-
particle composed of HA, chitosan, DPPC, PNIPAM-B, and
PF127 for targeted delivery of chemotherapeutics (DOX) into
multidrug-resistant cancer cells and their CSCs in vitro and
multidrug-resistant tumors in vivo. The HCLPN-D nano-
particles could significantly improve drug delivery into tumors
through the EPR effect of tumor vasculature after intravenous
injection into the tail vein (Figure 8). Moreover, the HCLPN-D
nanoparticles could quickly and irreversibly disassemble at cold
temperatures (<12 °C), which can induce burst release of most
encapsulated drug from the nanoparticles. Moreover, the cold-
triggered burst release of DOX together with the cold
temperature per se (to reduce the activity of membrane
transporters) can efficiently overcome the multidrug-resistant
capacity of NCI/RES-ADR cells (Figure 8). Furthermore,
CSCs enriched spheres derived from the multidrug-resistant
cancer cells were used to account for the multifaceted
mechanisms of cancer drug resistance. Our extensive in vitro
studies with both 2D cultured multidrug-resistant cells and 3D
microscale tumors (i.e., spheres) enriched with multidrug-
resistant CSCs as well as in vivo studies using the CSC-derived
tumors grown in mice, demonstrate the great potential of the
HCLPN-D nanoparticles with ice cooling for overcoming
different mechanisms associated with cancer multidrug
resistance for effective and safe cancer therapy.
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